Medovyne (Aciclovir)

Aciclovir is a nucleoside analogue that, after intracellular phosphorylation, competitively inhibits the viral DNA polymerase enzyme. This blocks the elongation of viral DNA strands, preventing replication of herpesviruses and thereby limiting the spread of infection within the host.

The specific dose and infusion rate of Medovyne are determined by the prescribing clinician based on the infection type, severity, patient weight, renal function and other clinical factors. Dosage regimens are individualized and should follow local prescribing guidelines.

Safety data for aciclovir during pregnancy are limited, and the product is classified as pregnancy category unknown. It should only be used when the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult a healthcare professional, as the drug may be excreted in milk.

To place an order, submit an enquiry on the Medovyne product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Compared with oral aciclovir tablets, the intravenous formulation provides higher and more consistent plasma concentrations, making it suitable for severe or disseminated infections and for patients unable to take oral medication. Alternative antivirals such as valacyclovir or famciclovir are oral prodrugs with similar efficacy for mild disease but lack the rapid systemic exposure achieved with IV aciclovir.

Medovyne should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Prior to administration, the solution should be inspected for particulate matter and discoloration, and used within the time frame specified in the product labeling after removal from refrigeration.

Medovyne is given by intravenous infusion, typically diluted in an appropriate compatible IV fluid and administered over a period determined by the prescribing clinician, often ranging from 30 minutes to several hours depending on the indication and patient renal function. Infusion should be performed under clinical supervision with monitoring for infusion‑related reactions.

The most serious adverse events reported with intravenous aciclovir include renal toxicity, especially in patients with pre‑existing kidney impairment or dehydration, and hypersensitivity reactions that may manifest as rash, fever, or anaphylaxis. Prompt recognition and discontinuation of the drug, along with supportive care, are essential to mitigate these risks.

Medovyne is contraindicated in patients with a known hypersensitivity to aciclovir or any component of the formulation. Caution is also advised for individuals with severe renal impairment who may be unable to clear the drug adequately, and for pregnant or breastfeeding women unless the therapeutic benefit outweighs potential risks.